Why the study?
Controversy had arisen on whether the use of renin-angiotensin system inhibitors in the context of COVID-19 would be beneficial or harmful.
Does treatment with ACEI or ARB reduce the risk of severe or fatal COVID-19 in hypertensive patients infected with COVID-19?
Does treatment with ACEI or ARB reduce the risk of severe or fatal COVID-19 in hypertensive patients infected with COVID-19?
The use of ACEI/ARB in hypertensive patients with COVID-19 is associated with a reduced risk of severe disease or death, supporting the continuation of these medications during infection.
No takes yet. Share an insight, caveat, or question.
Supports continuing ACEI/ARB in hypertensive COVID-19 patients; extends observational evidence of no increased severe or fatal outcomes.
Barochiner et al. (2020) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: